Pertuzumab for the treatment of ovarian cancer

Simon P Langdon, Dana Faratian, Yoko Nagumo, Peter Mullen, David J Harrison

Research output: Contribution to journalArticlepeer-review


Pertuzumab is a humanized monoclonal antibody that inhibits human epidermal growth factor receptor 2 (HER2) heterodimerization and has demonstrated clinical activity against both breast and ovarian cancer. To date, it is the most extensively studied HER2 inhibitor in ovarian cancer.
Original languageEnglish
Pages (from-to)1113-20
Number of pages8
JournalExpert opinion on biological therapy
Issue number7
Publication statusPublished - 2010


Dive into the research topics of 'Pertuzumab for the treatment of ovarian cancer'. Together they form a unique fingerprint.

Cite this